Decheng Capital

Portfolio

Investor Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Decheng Capital's primary investment focus?

Decheng Capital primarily invests in the Health Tech & Life Sciences sector, as indicated by all their portfolio companies and investment rounds falling within this sector.

Can you name some notable companies in Decheng Capital's portfolio?

Decheng Capital's portfolio includes ImmPACT Bio, which raised $137M, and Upstream Bio, which raised $400M. More companies can be found on startupim.

What is Decheng Capital's investment range?

Decheng Capital's investment range is between $111M and $200M per round.

Has Decheng Capital had any exits from its portfolio companies?

Yes, Decheng Capital had an exit in October 2024 with the acquisition of ImmPACT Bio by Lyell Immunopharma. The acquisition amount was undisclosed.

What is Decheng Capital's activity as a lead investor?

According to startupim data, Decheng Capital has a lead investor share of 0%, indicating they do not typically act as a lead investor in their funding rounds.

When did Decheng Capital make its first recorded investment?

Decheng Capital made its first recorded investment in January 2022.

What is the breakdown of Decheng Capital's investment stages?

Decheng Capital has participated in one A Round and two B Rounds, with one of the B Rounds being a follow-on investment.

How many new portfolio companies did Decheng Capital add in 2022?

Decheng Capital added two new portfolio companies in 2022, one in January and one in June.